Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 19;150(1):20.
doi: 10.1007/s00401-025-02928-w.

EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma

Cheyanne C Slocum  1 , Phuong Nguyen  1 , Meenakshi Vij  1 , Raymund L Yong  2 , Jorge Samanamud  1 , Satomi Hiya  1 , Carolina Maldonado-Díaz  1 , Melissa Umphlett  1 , Thenzing J Silva-Hurtado  1   2   3 , Kimmo J Hatanpaa  4 , Mariano S Viapiano  5   6 , Matija Snuderl  7 , Kalil G Abdullah  8   9 , Samuel K McBrayer  10   11 , Dolores Hambardzumyan  2   3   12 , Jamie M Walker  1   12   13 , Nadejda M Tsankova  1   12 , Timothy E Richardson  14   15
Affiliations

EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma

Cheyanne C Slocum et al. Acta Neuropathol. .
No abstract available

Keywords: EGFR amplification; TERT promoter mutation; Astrocytoma; Copy number variation (CNV); Glioblastoma; Homozygous CDKN2A/B deletion; IDH mutation; Oligodendroglioma; Tumor mutation burden (TMB); cIMPACT-NOW; + 7/-10.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: T.E.R. has received consulting fees from Servier Pharmaceuticals, which is unrelated to the current work. S.K.M. receives research funding from Servier Pharmaceuticals. S.K.M. and K.G.A. have intellectual property interests related to brain tumor metabolism and are co-founders of Gliomet. The results presented in this paper have not been published previously except in abstract form at the 101st American Association of Neuropathologists in 2025. The authors declare that they have no additional competing interests, conflicts of interest, or other relevant disclosures. Ethics approval and consent to participate: All tissue samples were obtained under approved Institutional Review Board (IRB) protocols and appropriate consent at the institutions of origin.

Figures

Fig. 1
Fig. 1
Prevalence and prognostic effect of EGFR alterations in IDH-mutant astrocytoma. a Oncoprint of the combined cohort (n = 790) including demographic, histologic, grade, and molecular information. b Percentage of cohort cases with EGFR alteration and/or CDKN2A/B loss. c Percentage of EGFR-altered cases with amplification and pathogenic activating mutation. d-f Kaplan–Meier curves of d progression-free survival (PFS) and e overall survival (OS) for cases in the combined cohort with wildtype/retained EGFR and CDKN2A/B (indicating the absence of EGFR amplification or mutation and absence of homozygous CDKN2A/B deletion, “EGFR & CDKN2A/B wildtype”), pathogenic EGFR alteration, and homozygous CDKN2A/B deletion, as well as OS for cases with f histologic grade 2–3, and g histologic grade 4. h Kaplan–Meier curve for cohort cases with wildtype/retained EGFR and CDKN2A/B, EGFR amplification, and pathogenic EGFR mutation. i-k Multivariate hazard ratio of pathogenic EGFR alteration compared to age, sex, histologic grade, and homozygous CDKN2A/B deletion on i PFS and j OS, as well as k EGFR amplification and pathogenic mutation compared to age, sex, histologic grade, and CDKN2A/B deletion on OS; Cox proportional hazards regression models also includes cohort/dataset source as a covariate
See this image and copyright information in PMC

References

    1. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 136:805–810. 10.1007/s00401-018-1913-0 - PMC - PubMed
    1. Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603–608. 10.1007/s00401-020-02127-9 - PMC - PubMed
    1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. 10.1093/neuonc/noab106 - PMC - PubMed
    1. Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M et al (2020) TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathol Commun 8:201. 10.1186/s40478-020-01078-2 - PMC - PubMed
    1. Ghosh HS, Patel RV, Claus EB, Gonzalez Castro LN, Wen PY, Ligon KL et al (2025) Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis. Neuro Oncol 27:993–1003. 10.1093/neuonc/noae258 - PMC - PubMed

LinkOut - more resources